Additionally, reverse transcriptase inhibitors, originally developed for HIV patients, have the potential to target endogenous retroviruses propose to be important SLE triggers (109) and reduce the IFN signature (110). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.